Knight Therapeutics Common Stock

Knight Therapeutics posts a common stock of $530M as of June 2026. That compares with $530M in the prior-year period — down 1.2% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Knight Therapeutics's common stock was $530M. The latest reading is $530M — a 1.2% year-over-year decrease (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Common Stock is one piece of Knight Therapeutics's financial statement story. At $530M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for KHTRF's common stock usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Knight Therapeutics's other metric pages and overview cover the third.